---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-21-000098"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2021-09-15T23:59:59+00:00"
generated_at: "2026-06-29T03:36:19.515371+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunovant appoints Renee Barnett as CFO; shareholders approve option repricing

## Summary
- Renee Barnett appointed CFO effective Oct 4, 2021; base salary $400K, signing bonus $500K, RSU bonus grant of 59,500 shares vesting Jan 1, 2022.
- Barnett also receives options for 333,000 shares and RSUs for 143,000 shares vesting over four years.
- Annual meeting results: 3 directors elected, EY ratified as auditor, say-on-pay frequency every year approved.
- Stockholders approved repricing of certain outstanding stock options under 2019 Equity Incentive Plan.
- Company plans to initiate pivotal MG trial and reinitiate TED and WAIHA programs.

## SEC filing metadata
- accession: 0001764013-21-000098
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2021-09-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/imvt-20210909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-21-000098
- JSON: https://secwatch.observer/filing/0001764013-21-000098.json
- Plain text: https://secwatch.observer/filing/0001764013-21-000098.txt

## Key facts
- Executive change
  Eric Venker was elected as Director at Immunovant, Inc..
  - Action: elected
  - Role: Director
  source text: Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm
- Executive change
  Atul Pande was elected as Director at Immunovant, Inc..
  - Action: elected
  - Role: Director
  source text: Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm
- Executive change
  Renee Barnett was appointed as Chief Financial Officer at Immunovant, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On September 14, 2021, Renee Barnett was appointed the Chief Financial Officer of Immunovant, Inc. effective October 4, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm
- Executive change
  Andrew Fromkin was elected as Director at Immunovant, Inc..
  - Action: elected
  - Role: Director
  source text: Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm
- Executive change
  Frank M. Torti was elected as Director at Immunovant, Inc..
  - Action: elected
  - Role: Director
  source text: Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.